Vittorio Velucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vittorio Velucci has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
Giovanni Defazio
Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy
17 shared publications- Marcello Mario Mascia
Neurology Unit, University Hospital of Cagliari, Cagliari, Italy
8 shared publications - Antonella Muroni
Neurology Unit, Azienda Ospedaliero Universitaria of Cagliari, Cagliari, Italy
6 shared publications Roberta Pellicciari
Department of Neurology ‘L. Amaducci’, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy
6 shared publications- Tommaso Ercoli
Department of Neurology, University of Sassari, Viale S. Pietro 10, 07100 Sassari, Italy
6 shared publications - Angelo Fabio Gigante
Section of Neurology, San Paolo Hospital Bari Italy
5 shared publications
Latest Publications
- 4 November 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
Predicting progression in Parkinson’s disease
- 4 November 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
Predicting progression in Parkinson’s disease
- Open Access
- 30 August 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Data‐Driven SuStaIn Model of Disability Progression in Amyotrophic Lateral Sclerosis
Objective: To determine whether ordinal Subtype and Stage Inference (SuStaIn) applied to routine ALSFRS‐R item scores can identify reproducible disability progression patterns in amyotrophic lateral sclerosis (ALS) and provide clinically meaningful staging. Methods: We analysed baseline ALSFRS‐R item responses from 866 PRO‐ACT participants. Ordinal SuStaIn inferred subtype‐specific sequences of functional deterioration and assigned each participant to a subtype and a SuStaIn‐derived functional stage. Longitudinal stability was assessed across 3625 consecutive follow‐up visit pairs from 697 participants. Structural reproducibility was evaluated in an independent cohort of 301 consecutive ALS patients. Associations of baseline subtype and stage with survival and subsequent ALSFRS‐R decline were examined using Cox and piecewise‐linear models. Results: A three‐subtype solution identified fine motor‐, gross motor‐ and bulbar‐predominant patterns of early disability. Within each subtype, SuStaIn reconstructed ordered multidomain sequences of functional deterioration and assigned each participant a SuStaIn‐derived stage. Subtype assignment was stable across 90.4% of consecutive visit pairs, and stage was non‐decreasing in 98.8%. Subtype‐specific event ordering was reproduced in the validation cohort. Higher baseline stage was associated with increased mortality risk in the fine motor‐ and gross motor‐predominant subtypes, but not clearly in the bulbar‐predominant subtype. Baseline stage showed subtype‐dependent, non‐linear associations with subsequent functional decline, with acceleration up to mid‐stage breakpoints in the fine motor‐ and gross motor‐predominant subtypes and less evident stage‐dependent acceleration in the bulbar‐predominant subtype. Interpretation: Routine ALSFRS‐R item‐level data can define clinically interpretable ALS progression subtypes and latent SuStaIn‐derived functional stages. Joint subtype‐stage modelling may refine prognostic stratification and support prognosis‐informed trial enrichment.
- 30 August 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Open AccessData‐Driven SuStaIn Model of Disability Progression in Amyotrophic Lateral Sclerosis
Objective: To determine whether ordinal Subtype and Stage Inference (SuStaIn) applied to routine ALSFRS‐R item scores can identify reproducible disability progression patterns in amyotrophic lateral sclerosis (ALS) and provide clinically meaningful staging. Methods: We analysed baseline ALSFRS‐R item responses from 866 PRO‐ACT participants. Ordinal SuStaIn inferred subtype‐specific sequences of functional deterioration and assigned each participant to a subtype and a SuStaIn‐derived functional stage. Longitudinal stability was assessed across 3625 consecutive follow‐up visit pairs from 697 participants. Structural reproducibility was evaluated in an independent cohort of 301 consecutive ALS patients. Associations of baseline subtype and stage with survival and subsequent ALSFRS‐R decline were examined using Cox and piecewise‐linear models. Results: A three‐subtype solution identified fine motor‐, gross motor‐ and bulbar‐predominant patterns of early disability. Within each subtype, SuStaIn reconstructed ordered multidomain sequences of functional deterioration and assigned each participant a SuStaIn‐derived stage. Subtype assignment was stable across 90.4% of consecutive visit pairs, and stage was non‐decreasing in 98.8%. Subtype‐specific event ordering was reproduced in the validation cohort. Higher baseline stage was associated with increased mortality risk in the fine motor‐ and gross motor‐predominant subtypes, but not clearly in the bulbar‐predominant subtype. Baseline stage showed subtype‐dependent, non‐linear associations with subsequent functional decline, with acceleration up to mid‐stage breakpoints in the fine motor‐ and gross motor‐predominant subtypes and less evident stage‐dependent acceleration in the bulbar‐predominant subtype. Interpretation: Routine ALSFRS‐R item‐level data can define clinically interpretable ALS progression subtypes and latent SuStaIn‐derived functional stages. Joint subtype‐stage modelling may refine prognostic stratification and support prognosis‐informed trial enrichment.
- 2 May 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5)
Multicenter validation of the Italian Pain in Dystonia Scale in idiopathic adult-onset cervical dystonia
The Pain in Dystonia Scale (PIDS) is a self-administered instrument to assess pain in dystonia, validated in cervical dystonia (CD). To translate and culturally adapt the PIDS into Italian following a standardized forward-backward procedure and to validate the resulting Italian version (I-PIDS) in patients with idiopathic adult-onset CD as part of a multicenter effort aimed at evaluating its clinimetric properties across dystonia subtypes. I-PIDS was completed by 64 Italian patients with cervical dystonia from 16 centers, three months or more after their last botulinum toxin treatment. Standard clinimetric analyses were performed. Acceptability was optimal, with no missing data. Score distributions met expected criteria, with mean-median differences <10% of the maximum score for all body regions except the jaw, and no floor or ceiling effects. Internal consistency was satisfactory for all pain regions (α = 0.81-0.91) and for functional impact (α = 0.83) and modulating factors (α = 0.73-0.74). Convergent validity was demonstrated by a moderate correlation between neck pain scores and the Global Dystonia Rating Scale (r = 0.39, p = 0.03), while divergent validity was supported by the absence of correlation with the Montreal Cognitive Assessment (r = 0.02, p = 0.90). Exploratory analyses suggested that pain severity in CD was not associated with age, sex, education, age at onset, or dystonia duration, and that pain frequently involved multiple body regions, independently of dystonia distribution. These findings support the validity of I-PIDS and provide further insight into the pattern of pain in CD.
- 2 May 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5)
Multicenter validation of the Italian Pain in Dystonia Scale in idiopathic adult-onset cervical dystonia
The Pain in Dystonia Scale (PIDS) is a self-administered instrument to assess pain in dystonia, validated in cervical dystonia (CD). To translate and culturally adapt the PIDS into Italian following a standardized forward-backward procedure and to validate the resulting Italian version (I-PIDS) in patients with idiopathic adult-onset CD as part of a multicenter effort aimed at evaluating its clinimetric properties across dystonia subtypes. I-PIDS was completed by 64 Italian patients with cervical dystonia from 16 centers, three months or more after their last botulinum toxin treatment. Standard clinimetric analyses were performed. Acceptability was optimal, with no missing data. Score distributions met expected criteria, with mean-median differences <10% of the maximum score for all body regions except the jaw, and no floor or ceiling effects. Internal consistency was satisfactory for all pain regions (α = 0.81-0.91) and for functional impact (α = 0.83) and modulating factors (α = 0.73-0.74). Convergent validity was demonstrated by a moderate correlation between neck pain scores and the Global Dystonia Rating Scale (r = 0.39, p = 0.03), while divergent validity was supported by the absence of correlation with the Montreal Cognitive Assessment (r = 0.02, p = 0.90). Exploratory analyses suggested that pain severity in CD was not associated with age, sex, education, age at onset, or dystonia duration, and that pain frequently involved multiple body regions, independently of dystonia distribution. These findings support the validity of I-PIDS and provide further insight into the pattern of pain in CD.
- 27 March 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 2024-2025
Reply: “Segmental vs. Multifocal: The 2025 Dystonia Classification Is Helpful”
- 27 March 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 2024-2025
Reply: “Segmental vs. Multifocal: The 2025 Dystonia Classification Is Helpful”
- Open Access
- 18 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1933-1939
The Pain in Dystonia Scale (PIDS)—Validation in Craniofacial and Upper Limb Dystonia
Background: Pain is one of the most disabling non‐motor symptoms in adult‐onset isolated dystonia (AOID). The Pain in Dystonia Scale (PIDS) was developed and validated in cervical dystonia. Its applicability to other focal subtypes remains unknown. Objectives: To validate the PIDS in patients with craniofacial and upper limb dystonia, expanding its use beyond cervical dystonia. Methods: We conducted a two‐phase cross‐sectional validation study in independent cohorts from Calgary, Canada and Italy. The Calgary pilot cohort ( n = 20) included participants with craniofacial and/or upper limb dystonia who completed the PIDS twice for test–retest reliability and a battery of comparator scales. The Italian cohort ( n = 109) was recruited through the Italian Dystonia Registry and completed the PIDS after cross‐cultural adaptation. Internal consistency, test–retest reliability, construct validity, and distribution properties were assessed using established psychometric standards. Results: Pain was highly prevalent (90.0% Calgary; 96.3% Italy), with anatomical distribution varying by dystonia subtype. Internal consistency was high across both cohorts (Cronbach's alpha 0.82–0.96), with minimal floor and ceiling effects. Test–retest reliability in the pilot cohort was excellent (ICC = 0.85). Construct validity was supported by strong correlations between PIDS scores and established pain and quality‐of‐life measures. Functional impact and pain modulators were consistently reported across cohorts, with stress identified as the most frequent aggravating factor and rest and stretching as common relieving factors. Conclusions: The PIDS demonstrates reliability, validity, and feasibility in craniofacial and upper limb dystonia, supporting its adoption for evaluating dystonia‐related pain in clinical and research settings across the main focal subtypes.
- 18 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1933-1939
Open AccessThe Pain in Dystonia Scale (PIDS)—Validation in Craniofacial and Upper Limb Dystonia
Background: Pain is one of the most disabling non‐motor symptoms in adult‐onset isolated dystonia (AOID). The Pain in Dystonia Scale (PIDS) was developed and validated in cervical dystonia. Its applicability to other focal subtypes remains unknown. Objectives: To validate the PIDS in patients with craniofacial and upper limb dystonia, expanding its use beyond cervical dystonia. Methods: We conducted a two‐phase cross‐sectional validation study in independent cohorts from Calgary, Canada and Italy. The Calgary pilot cohort ( n = 20) included participants with craniofacial and/or upper limb dystonia who completed the PIDS twice for test–retest reliability and a battery of comparator scales. The Italian cohort ( n = 109) was recruited through the Italian Dystonia Registry and completed the PIDS after cross‐cultural adaptation. Internal consistency, test–retest reliability, construct validity, and distribution properties were assessed using established psychometric standards. Results: Pain was highly prevalent (90.0% Calgary; 96.3% Italy), with anatomical distribution varying by dystonia subtype. Internal consistency was high across both cohorts (Cronbach's alpha 0.82–0.96), with minimal floor and ceiling effects. Test–retest reliability in the pilot cohort was excellent (ICC = 0.85). Construct validity was supported by strong correlations between PIDS scores and established pain and quality‐of‐life measures. Functional impact and pain modulators were consistently reported across cohorts, with stress identified as the most frequent aggravating factor and rest and stretching as common relieving factors. Conclusions: The PIDS demonstrates reliability, validity, and feasibility in craniofacial and upper limb dystonia, supporting its adoption for evaluating dystonia‐related pain in clinical and research settings across the main focal subtypes.
- 13 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 151
Improvement of Pisa syndrome in Parkinson’s disease following continuous subcutaneous infusion of foslevodopa/foscarbidopa
- 13 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 151
Improvement of Pisa syndrome in Parkinson’s disease following continuous subcutaneous infusion of foslevodopa/foscarbidopa
- 10 January 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 145, 111856
Facial-onset SOD1 amyotrophic lateral sclerosis: A case report and systematic review
- 10 January 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 145, 111856
Facial-onset SOD1 amyotrophic lateral sclerosis: A case report and systematic review
- Open Access
- 12 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70468
Olfactory Dysfunction and/or RBD for Mapping Parkinson's Disease Subtypes?
- 12 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70468
Open AccessOlfactory Dysfunction and/or RBD for Mapping Parkinson's Disease Subtypes?
- 5 December 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 480, 125691
Is segmental/multifocal onset a distinct presentation of idiopathic adult-onset dystonia?
- 5 December 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 480, 125691
Is segmental/multifocal onset a distinct presentation of idiopathic adult-onset dystonia?